Clinical trials: Lymphatic System Neoplasm
Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
MB-CART19.1 in Patients With R/R ALL
Precursor-B acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Despite major advances in ALL therapy, 20% of children and 40-50% of adults fail state-of-the art first-line treatment.
- Trial name
- NCT03321123
- Testing
- MB-CART19.1
- Volunteers
- 10 people
- Sponsor
- Shanghai Children's Medical Center
Lymphoma, Leukemia
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
The purpose of this study is to test any good and bad effects of the study drug, CPI-613.
- Trial name
- NCT03793140
- Testing
- CPI-613
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01016379
- Testing
- DNA analysis, biologic sample preservation procedure, laboratory biomarker analysis
- Volunteers
- 1,000 people
- Sponsor
- Children's Oncology Group
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
The Impact of COVID-19 on Pulmonary Procedures
This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05022446
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease, Leukemia
Bone Marrow Transplantation in Treating Patients With Leukemia
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00006451
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight
Hepatoprotective Measures for Children at High Risk of NAFLD
Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure.
- Conditions
- Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia
- Trial name
- NCT06918080
- Testing
- Ursodeoxycholic Acid 250 Mg Oral Capsule, Omega -3 fatty acids, Physical exercise
- Where
- 2 sites in Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
- Trial name
- NCT03097770
- Testing
- anti-CD19/20-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Hematologic Malignancies, Acute Myeloid Leukemia
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
The purpose of this study is to determine the efficacy and safety of transplanting StemEx® in patients with certain hematological malignancies.
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia
- Trial name
- ExCell (NCT00469729)
- Testing
- StemEx®
- Where
- 30 sites in United States, Hungary and 3 more
- Volunteers
- 101 people
- Sponsor
- Gamida Cell -Teva Joint Venture Ltd.
Hodgkin's Lymphoma
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Objective: The primary objective of the study is to evaluate the effect of R-mabHDI in patients with late stage, widespread stage and recurrent Lymphocytic Predominant Hodgkin's Lymphoma.
- Trial name
- NCT00816959
- Testing
- R-mabHDI and ABVD, ABVD
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- American Scitech International
Leukemia
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01232842
- Testing
- cytogenetic analysis, HUMARA assay, fluorescence activated cell sorting
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Aplastic Anemia
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Patients have been diagnosed with severe Aplastic Anemia that have not responded to treatment with immunosuppressive therapy (drugs that suppress the immune system, for example Steroids).
- Trial name
- NCT00578903
- Testing
- Cytoxan, Campath, Total Body Irradiation (TBI)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Baylor College of Medicine
HIV, AIDS
HIV Indicator Diseases Survey Across Europe - UK Arm
In Europe many patients infected with HIV remain undiagnosed, although this percentage varies between 15-80% across the continent. In the UK it is estimated to be 27%.
- Conditions
- HIV, AIDS, Indicator Diseases/Indicator Conditions
- Trial name
- NCT01196468
- Testing
- HIV test (serological or salivary), Interview
- Where
- 2 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myelogous Leukemia/Other Leukemia, Acute Leukemias
Providing Access to Cord Blood Units for Transplants
Background: Cord blood banks have been set up to collect and store umbilical cord blood for transplants. These transplants are used to treat different types of cancer.
- Conditions
- Chronic Myelogous Leukemia/Other Leukemia, Acute Leukemias, MDS/MPS, Multiple Myeloma
- Trial name
- NCT01479582
- Testing
- Access to unlicensed cord blood units
- Sponsor
- National Cancer Institute (NCI)
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy
RATIONALE: Silymarin (milk thistle extract) is an herb that may be effective in treating liver disorders caused by cancer therapy.
- Trial name
- NCT00055718
- Testing
- silymarin
- Where
- 8 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
This is a single dose escalation study to evaluate the safety and clinical activity of ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7 positive T cell malignancies.
- Conditions
- T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Lymphoma
- Trial name
- NCT05127135
- Testing
- ThisCART7 cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
Many patients suffering various malignant and non-malignant diseases need hematopoietic stem cell transplantation from a healthy person. In the majority of cases there is no matched related or unrelated donor.
- Trial name
- NCT00458250
- Testing
- Haploidentical hematopoietic stem cell transplantation, Busulfan, Cyclophosphamide
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Tehran University of Medical Sciences
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Pre-cancerous Lymphoproliferative Disorders
Oxford Pre-cancerous Lymphoproliferative Disorders Study
OxPLoreD is an observational cohort study to identify clinical, genomic and immunological predictive markers of progression to malignant disease.
- Trial name
- OxPLoreD (NCT04023747)
- Where
- 17 sites in United Kingdom
- Volunteers
- 574 people
- Sponsor
- University of Oxford
Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukaemia
CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia
The goal of this observational study is to evaluate the efficacy of the treatment with approved CAR-T cells in Italy in pediatric and adult patients with acute B-cell lymphoblastic leukemia.
- Trial name
- NCT07623655
- Volunteers
- 107 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.